Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab.
erythrodermic psoriasis
hemodialysis
psoriasis
secukinumab
therapy
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
09
02
2020
revised:
17
03
2020
accepted:
26
03
2020
pubmed:
3
4
2020
medline:
15
5
2021
entrez:
3
4
2020
Statut:
ppublish
Résumé
Erythrodermic psoriasis is a severe, life-threatening condition with additional complications, when occurring in hemodialyzed patients, as the majority of treatments are contraindicated. A 44-years-old man, of Philippine origins, with a 15-years-history of psoriasis treated with cyclosporine developed progressive hypertension and renal insufficiency. Despite drug dismission, renal function worsen to end-stage, and hemodialysis was necessary three times a week. Phototherapy was not able to control the skin condition, progressing to erythroderma, and after nephrology consultation, the patient consent to the off-label secukinumab treatment, at the standard regimen (300 mg subcutaneously once weekly at weeks 0-4 followed by 300 mg every 4 weeks). Seven days after the first injection, a rapid improvement was noted, with the psoriasis area severity index (PASI) score passing from 31.5 to 17.6. At the 52-week-follow-up visit, the patient was completely clarified, without any side effects. The case supports secukinumab effectiveness and safety in difficult patients, including erythrodermic psoriasis with end-stage renal failure, as drug plasma levels seem not to be affected by hemodialysis. Results are rapidly achieved, and long term maintained, with the additional advantage of a very comfortable monthly administration.
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
secukinumab
DLG4EML025
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13348Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Lebwohl M. Psoriasis. Lancet. 2008;36:1197.
Singh RK, Lee KM, Ucmak D, et al. Eythrodermic psoriasis: Patophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:93-104.
Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62:655-662.
O'Quinn RP, Miller JL. The Effectiveness of tumor necrosis factor-alpha antibody (Infliximab) in treating recalcitrant psoriasis. Arch Dermatol. 2002;138:644-648.
Rongioletti F, Borenstein M, Kirsner R, Kerdel F. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatolog Treat. 2003;14(4):222-225.
Lisby S, Gniadecki R. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. Acta Derm Venereol. 2004;84:247-248.
Fiehn C, Andrassy K. Case Number 29: Hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade). Ann Rheum Dis. 2004;63:232.
Heikkilä H, Ranki A, Cajanus S, et al. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol. 2005;141:1607-1610.
Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol. 2006;155(1):156-159.
Poulalhon N, Begon E, Lebbé C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007;156(2):329-336.
Takahashi MD, Castro LG, Romiti R. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol. 2007;157(4):828-831.
Piqué-Durán E, Pérez-Cejudo J. Eritrodermia psoriásica tratada con etanercept. Acta Dermosifiliogr. 2007;98:508-510.
Richetta AG, Maiani E, Carlomagno V, et al. Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab. Dermatol Ther. 2009;22(Suppl 1):S16-S18.
Santos-Juanes J, Coto-Segura P, Mas-Vidal A, Galache Osuna C. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol. 2010;162(5):1144-1146.
Wang TS, Tsai TF. Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series. J Dermatol. 2011;38:1096-1099.
Torii H, Nakagawa H. Japanese Infliximab Study Investigators. Long term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol. 2011;38:321-334.
Castiñeiras I, Fernàndez-Diaz L, Juárez Y, Lueiro M. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies. J Dermatol. 2012;39:730-731.
Viguier M, Pagès C, Aubin F, et al. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol. 2012;167:417-423.
Buggiani G, D'Erme AM, Krysenka A, Pescitelli L, Lotti T, Prignano F. Efficacy of ustekinumab in sub-erythrodermic psoriasis: when TNFblockers fail. Dermatol Ther. 2012;25:283-285.
Saraceno R, Talamonti M, Galluzzo M, Chiricozzi A, Costanzo A, Chimenti S. Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases. Case Rep Dermatol. 2013;5:254-259.
Koutsoukou XA, Papadavid E, Theodoropoulos K, Rigopoulos D. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission. Dermatol Ther. 2014;27:257-259.
Stinco G, Piccirillo A, Errichetti E, Bergamo S, Patrone P. Treatment of recalcitrant erythrodermic psoriasis with ustekinumab. Eur J Dermatol. 2014;24:387-390.
Pescitelli L, Dini V, Gisondi P, et al. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis. J Dermatol Sci. 2015;78(2):149-151.
Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355-362.
Romero-Maté A, García-Donoso C, Martinez-Morán C, Hernández-Núñez A, Borbujo J. Long-term management of erythrodermic psoriasis with anti-TNF agents. Dermatol Online J. 2010;16(6):15.
Mugheddu C, Atzori L, Lappi A, Pau M, Murgia S, Rongioletti F. Successful secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2017;31:e420-e421.
Yamasaki K, Nakagawa H, Kubo Y, Ootaki K, Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741-751.
Talat H, Wahid Z, Feroz F, Sajid M. Erythrodermic psoriasis and hepatitis C infection treated with pegylated interferon and anti-TNFα α(Etanercept) therapy. J Coll Physicians Surg Pak. 2017;27(9):S77-S79.
Weng HJ, Wang TS, Tsai TF. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series. Br J Dermatol. 2017;78:1439-1440.
Mateu-Puchades A, Santos-Alarcón S, Martorell-Calatayud A, Pujol-Marco C, Sánchez-Carazo JL. Erythrodermic psoriasis and secukinumab: our clinical experience. Dermatol Ther. 2018;31:e12607.
Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529-539.
Shibata T, Muto J, Takama H, Yanagishita T, Ito T, Watanabe D. Case of psoriatic erythroderma induced by the discontinuation of the chronic use of topical steroid after dialysis initiation and successfully treated with secukinumab. J Dermatol. 2019;46:e119-e120.
Megna M, Gallo L, Balato N, Balato A. A case of erythrodermic psoriasis successfully treated with ixekizumab. Dermatol Ther. 2019;32(2):e12825.
Damiani G, Pacifico A, Russo F, et al. Use of secukinumab in a cohort of erythrodermic psoriatic patients: a pilot study. J Clin Med. 2019;8:E770.
Larquey M, Girard C, Sbidian E, Richard MA, Aubin F, Schmutz JL. Efficacy of biologics in psoriasis patients under hemodialysis. Eur J Dermatol. 2017;27:531-533.
Cassano N, Vena GA. Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection. Int J Dermatol. 2008;47:980-981.
De Unamuno BB, Sánchez RB, Martínez VO, Carazo JL. Efficacy and safety of ustekinumab in a patient with chronic renal failure on hemodialysis. Int J Dermatol. 2014;42:731-734.
Larquey M, Poreaux C, Cuny JF, Barbaud A, Schmutz JL. Good efficacy and tolerability of ustekinumab in a patient with severe psoriasis under hemodialysis. Eur J Dermatol. 2014;24:618-619.
Kusakari Y, Yamasaki K, Takahashi T, et al. Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: a case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure. J Dermatol. 2015;42:1-4.
Umezawa Y, Hayashi M, Kikuchi S, et al. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis. J Dermatol. 2015;42:731-734.
Nimmannitya K, Tateishi C, Mizukami Y, et al. Successful treatment with ustekinumab of psoriasis vulgaris in a patient undergoing hemodialysis. J Dermatol. 2016;43(1):92-94.
Babino G, Esposito M, Bianchi L, Giunta A. Long-term treatment with etanercept monotherapy in a hemodialyzed patient with moderate-to-severe plaque-type psoriasis and psoriatic arthritis. G Ital Dermatol Venereol. 2018;153(6):882-884.
Mukai M, Kurihara Y, Ito Y, et al. Successful treatment with secukinumab of three psoriatic patients undergoing dialysis. J Dermatol. 2020;47:e26-e28.